These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1237 related items for PubMed ID: 26003022

  • 1. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.
    Kufner S, Cassese S, Valeskini M, Neumann FJ, Schulz-Schüpke S, Hoppmann P, Fusaro M, Schunkert H, Laugwitz KL, Kastrati A, Byrne RA, ISAR-DESIRE 3 Investigators.
    JACC Cardiovasc Interv; 2015 Jun; 8(7):877-84. PubMed ID: 26003022
    [Abstract] [Full Text] [Related]

  • 2. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial.
    Kufner S, Joner M, Schneider S, Tölg R, Zrenner B, Repp J, Starkmann A, Xhepa E, Ibrahim T, Cassese S, Fusaro M, Ott I, Hengstenberg C, Schunkert H, Abdel-Wahab M, Laugwitz KL, Kastrati A, Byrne RA, ISAR-DESIRE 4 Investigators.
    JACC Cardiovasc Interv; 2017 Jul 10; 10(13):1332-1340. PubMed ID: 28683939
    [Abstract] [Full Text] [Related]

  • 6. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.
    Loh JP, Stella PR, Sangiorgi G, Silber S, Stahnke S, von Strandmann RP, Torguson R, Waksman R.
    Cardiovasc Revasc Med; 2014 Jan 10; 15(1):23-8. PubMed ID: 24444473
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study.
    Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B.
    EuroIntervention; 2015 Dec 10; 11(8):926-34. PubMed ID: 25169589
    [Abstract] [Full Text] [Related]

  • 10. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW.
    JACC Cardiovasc Interv; 2013 Dec 10; 6(12):1263-6. PubMed ID: 24239202
    [Abstract] [Full Text] [Related]

  • 11. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DE, ENDEAVOR IV Investigators.
    JACC Cardiovasc Interv; 2010 Oct 10; 3(10):1043-50. PubMed ID: 20965463
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.
    Claessen BE, Henriques JPS, Vendrik J, Boerlage-van Dijk K, van der Schaaf RJ, Meuwissen M, van Royen N, Gosselink ATM, van Wely MH, Dirkali A, Arkenbout EK, Piek JJ, Baan J.
    Catheter Cardiovasc Interv; 2019 Feb 01; 93(2):216-221. PubMed ID: 30232824
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Drug-eluting stents in patients on chronic hemodialysis: paclitaxel-eluting stents vs. limus-eluting stents.
    Sardi GL, Loh JP, Torguson R, Laynez-Carnicero A, Kitabata H, Xue Z, Satler LF, Pichard AD, Waksman R.
    Cardiovasc Revasc Med; 2014 Mar 01; 15(2):86-91. PubMed ID: 24684759
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.